Description

Cagrilintide – Long‑Acting Appetite Control Peptide

Overview
Cagrilintide is a long‑acting synthetic analogue of the hormone amylin, developed to influence appetite and support weight management. It activates amylin and related receptors involved in regulating feelings of fullness, slowing gastric emptying, and reducing food intake. Because of its extended half‑life, it is designed for once‑weekly use to help maintain appetite suppression and support metabolic effects over time.

Benefits

• Supports reductions in appetite and overall food intake
• Encourages feelings of fullness and satiety
• Can contribute to meaningful weight loss in research settings
• May support improved glucose control and metabolic health
• Once‑weekly dosing adds convenience

Mechanism of Action
Cagrilintide works by mimicking the action of the naturally occurring hormone amylin. When it binds to amylin and related receptors in the brain, it slows how quickly the stomach empties after eating, increases satiety signals, and reduces hunger. These effects help decrease meal size and overall caloric intake.

Dosing (Research Use Only)

• Administration: Subcutaneous injection once per week
• Typical target dose in research: around 2.4 mg per week
• Dose escalation: Commonly started at a low weekly dose (e.g., 0.3 mg) and gradually increased over several weeks to improve tolerance
• Injection sites: Abdomen, thigh, or upper arm

Expected Results

• Appetite reduction typically develops early in treatment
• Noticeable decreases in hunger and caloric intake over several weeks
• Significant weight reduction seen in extended research use
• Consistent results may depend on adherence to diet and lifestyle support

Side Effects

• Common: Nausea, vomiting, constipation, diarrhea, and abdominal discomfort
• Injection site reactions such as redness or irritation
• Fatigue and mild headaches may occur
• Some individuals experience gastrointestinal effects more strongly during dose increases
• Most side effects are mild to moderate and tend to lessen over time

Warnings

• Not approved for general human use; experimental and under clinical evaluation
• Not recommended during pregnancy or breastfeeding
• Gradual dose increases help reduce early side effects
• Individuals with serious medical conditions should seek guidance from a healthcare professional before use
• Appetite suppression and slowed digestion can influence nutrient intake and hydration

Summary
Cagrilintide is a long‑acting peptide designed to help regulate appetite and support weight loss by mimicking the hormone amylin. It is administered once weekly and may reduce hunger and support metabolic improvements. While generally well tolerated in research contexts, it is still experimental and not approved for routine clinical use.